NCT04261426 is a Phase 2, PHASE3 clinical trial of Intravenous Immunoglobulin in 2019-nCoV, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT04261426?

NCT04261426 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT04261426?

Interventions in NCT04261426: Intravenous Immunoglobulin, Standard care.

Is NCT04261426 still recruiting?

NCT04261426 is currently status unknown. Last updated 7 February 2020.

Last reviewed 2020-02-07 · How we verify

NCT04261426

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia

Status unknown Phase 2, PHASE3 Last updated 7 February 2020

What this trial tests

Phase 2, PHASE3 trial testing Intravenous Immunoglobulin in 2019-nCoV in 80 participants. Status unknown.

Timeline

10 February 2020

Primary endpoint
30 April 2020

30 June 2020

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	10 February 2020
Primary completion	30 April 2020
Estimated completion	30 June 2020

Drugs / interventions tested

Intravenous Immunoglobulin — full drug profile →
Standard care — full drug profile →

Conditions studied

2019-nCoV — all drugs for 2019-nCoV →

Sponsor

Peking Union Medical College Hospital

Who can join

18 and older, any sex, with 2019-nCoV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this single-center, randomized, open-label, controlled study, the investigators will evaluate the efficacy and safety of Intravenous Immunoglobulin (IVIG) in combination with standard care for severe 2019 novel coronavirus (2019-nCoV) pneumonia.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Liu B, Li M, Zhou Z, Guan X, et al · · 2020 · cited 507× · PMID 32291137 · DOI 10.1016/j.jaut.2020.102452
COVID-19: Transmission, prevention, and potential therapeutic opportunities.
Lotfi M, Hamblin MR, Rezaei N. · · 2020 · cited 447× · PMID 32474009 · DOI 10.1016/j.cca.2020.05.044
A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
Tu YF, Chien CS, Yarmishyn AA, Lin YY, et al · · 2020 · cited 406× · PMID 32290293 · DOI 10.3390/ijms21072657
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.
Lythgoe MP, Middleton P. · · 2020 · cited 247× · PMID 32291112 · DOI 10.1016/j.tips.2020.03.006
Clinical trials on drug repositioning for COVID-19 treatment.
Rosa SGV, Santos WC. · · 2020 · cited 225× · PMID 32256547 · DOI 10.26633/rpsp.2020.40
Pharmaco-Immunomodulatory Therapy in COVID-19.
Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, et al · · 2020 · cited 190× · PMID 32696108 · DOI 10.1007/s40265-020-01367-z
COVID-19 and Cancer: a Comprehensive Review.
Gosain R, Abdou Y, Singh A, Rana N, et al · · 2020 · cited 187× · PMID 32385672 · DOI 10.1007/s11912-020-00934-7
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Chai KL, Valk SJ, Doree C, et al · · 2020 · cited 148× · PMID 32648959 · DOI 10.1002/14651858.cd013600.pub2

Verify or expand the search:

Other trials of Intravenous Immunoglobulin

Trials testing the same drug.

NCT03994783 — Transplant Antibody-Mediated Rejection: Guiding Effective Treatments · Phase 3 · terminated
NCT02586051 — A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal D · Phase 1 · completed

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04261426 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 7 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04261426.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing